Analysts Remain Bullish Despite Caribou's Allogeneic CAR-T Hit By Durability

Vandana Singh
2 min read
0
In this article:

  • Caribou Biosciences Inc (NASDAQ: CRBU) announced the presentation of additional initial clinical data from its ANTLER Phase 1 trial for CB-010 in relapsed or refractory B cell non-Hodgkin lymphoma (r/r B-NHL).

  • Following a single dose at the initial dose level of 40 million CAR-T cells, a 100% complete response (CR) rate (6 of 6 patients) was observed as the best response.

  • Related: Caribou's Lymphoma Candidate Shows 100% Response Rate In Early-Stage Study.

  • At 6 months following the single dose of CB-010, 40% of patients remained in CR (2 of 5 patients) as of the May 13 data cutoff date.

  • One patient suffered grade 3 immune effector cell-associated neurotoxicity syndrome that resolved in 39 hours. Still, none of the patients experienced graft-versus-host disease or grade 2 or greater cytokine release syndrome (CRS). Two patients had grade 1 CRS.

  • Caribou has begun enrolling patients at the second dose level, 80 million CAR-T cells. Doubling the dose could drive longer-lasting responses.

  • "Our conviction is intact that the recent dataset positions CRBU to potentially differentiate vs. competitors in a meaningful and favorable way as data matures and the company explores larger patient numbers and higher dose(s)," SVB Securities wrote.

  • HC Wainwright says that CB-010's response rate and the complete response rate are more competitive than those seen with the FDA-approved CAR-T agents.

  • It notes that Gilead Sciences Inc's (NASDAQ: GILD) Yescarta demonstrated a 74% ORR (54% CR) and 94% ORR (79% CR) in DLBCL and FL, respectively, and Novartis AG's (NYSE: NVS) Kymriah demonstrated a 53% ORR (39% CR) and 87% ORR (68% CR) in DLBCL and FL, respectively.

  • Price Action: CRBU shares are down 25.70% at $5.16 during the market session on the last check Monday.

Latest Ratings for CRBU

Date

Firm

Action

From

To

Feb 2022

RBC Capital

Initiates Coverage On

Outperform

Feb 2022

Brookline Capital

Initiates Coverage On

Buy

Dec 2021

Oppenheimer

Initiates Coverage On

Outperform

View More Analyst Ratings for CRBU

View the Latest Analyst Ratings

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Advertisement

Recommended Stories